In theory, biosimilars will be comparable to proven biotherapeutics with regard to safety and efficacy—but available at a radically lower cost. Will this promise be fulfilled? This month's feature takes a look at the pros and cons of these agents.
All content on the Academy’s website is protected by copyright law and the Terms of Service. This content may not be reproduced, copied, or put into any artificial intelligence program, including large language and generative AI models, without permission from the Academy.